Clinical Study Design

- **Open label, observational study**
- **Inclusion**
  - Male and female (Adult)
  - History of allergic rhinitis (≥ 1 year)
  - Positive skin prick test (RAST) to *Parietaria officinialis* pollen
  - Baseline nasal and/or ocular symptoms of seasonal rhinitis
- **Dosing:** 2 tablets per day. In the morning and evening at or after mealtime
- **Treatment period:** 30 day duration
- **Data collection:** Baseline and D30

Evaluation Methods

- **Evaluation methods:**
  - Relief of signs and symptoms of ARC using the Total Symptoms Score and Scale (TSS):
    - 6 clinical parameters graded from 0-3 based on episodes per day

      0 = absence

      1 = 1-5 episodes

      2 = 6-10 episodes

      3 = ≥11 episodes
  - Reduction of the consumption of anti-allergic drugs (patient recorded at baseline and D30)

- **Safety:** Monitoring adverse events (AEs)

AllerVarx™ Efficacy

Reduction of the average of the scores of individual symptoms measured at baseline and after 30D of AllerVarx™ use



Highly significant reduction ($p<0.0001$) of each individual symptom compared to baseline

AllerVarx™ Efficacy

Reduction of the average score of the Total Symptom Score Scale at baseline and after 30 days of AllerVarx™ use



Gender	Symptom score reduction
Females	72%
Males	68%

Highly significant reduction in Total Symptom Scores of the overall symptoms by approximately 70%

AllerVarx™ Efficacy

Reduction of consumption of anti-allergic drugs by gender

	Female (n=16)	Male (n=7)
Average Age	44	46
Reduction of anti-allergic drugs	76%	67%

Reduction of use of antihistamines by 73% by end of study

Efficacy & Safety Summary

- **AllerVarx™ containing quercetin, perilla dry extract and vitamin $D_{3,}$ is effective in reducing nasal and / or ocular symptoms in subjects with seasonal allergic rhinitis**
  - TSS: highly significant reduction (p> 0.001) of the overall symptoms, with a reduction of approximately 70%
  - Individual Symptoms: highly significant reduction (p> 0.001) of each symptom
  - Reduction of use of anti-allergic drugs (73%)

- **Well tolerated**
  - No side effects recorded
  - All subjects completed the study